# A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec

> **NCT05575011** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Biogen** · enrollment: 62 (actual)

## Conditions studied

- Healthy Volunteer
- Muscular Atrophy, Spinal

## Interventions

- **DRUG:** BIIB115
- **DRUG:** BIIB115-Matching Placebo

## Key facts

- **NCT ID:** NCT05575011
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-10
- **Primary completion:** 2031-11-14
- **Final completion:** 2031-11-14
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05575011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05575011, "A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05575011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*